Promising though not yet proven: Emerging strategies to promote myocardial salvage

Catheterization and Cardiovascular Interventions

Volumn 68, Issue 4, 2006, Pages 596-606

  Rizik, David G ^a   Klassen, Kevin J ^a   Dowler, Denise A ^a   Villegas, Bernard J ^a   Dixon, Simon R ^a  

^a HonorHealth and the Scottsdale Lincoln Health Network   (United States)

Author keywords

Acute coronary syndrome; Angiography coronary; Percutaneous coronary intervention

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BUSPIRONE; FLUOSOL; PETHIDINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SEROTONIN 1A AGONIST; TG 100115; UNCLASSIFIED DRUG; WORTMANNIN;

ANGIOCARDIOGRAPHY; CONGESTIVE HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE FUNCTION; HUMAN; HYPERBARIC OXYGEN; INDUCED HYPOTHERMIA; LEUKOCYTE; METABOLIC REGULATION; MUSCLE CELL; NONHUMAN; OXYGEN DELIVERY DEVICE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANIMALS; CORONARY ANGIOGRAPHY; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; HYPOTHERMIA, INDUCED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 33749607408     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20892     Document Type: Review

References (93)

1. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
2. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317:850-855.
3. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
4. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998;32:1312-1319.
5. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction Trials. J Am Coll Cardiol 1992;20:1452-1459.
6. Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc-sestamibi imaging predicts subsequent mortality. Circulation 1995;92:334-341.
7. Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002;39:30-36.
8. Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002;40:1928-1934.
9. O'Neill WW, Dixon SR. The year in interventional cardiology. J Am Coll Cardiol 2004;43:875-890.
10. Dixon SR, Bartorelli AL, O'Neill WW, et al. Initial experience with hyperoxemic reperfusion after primary angioplasty for acute myocardial infarction results of a pilot study utilizing intracoronary aqueous oxygen therapy. J Am Coll Cardiol 2002;39:387-392.
11. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(3, Suppl):II38-II48.
12. Chien GL, Wolff RA, Davis RF, van Winkle DM. "Normothermic range" temperature affects myocardial infarct size. Cardiovasc Res 1994;28:1014-1017.
13. Duncker DJ, Klassen CL, Ishibashi Y, Herrlinger SH, Pavek TJ, Bache RJ. Effect of temperature on myocardial infarction in swine. Am J Physiol 1996;270:H1189-H1199.
14. Hale SL, Dave RH, Kloner RA. Regional hypothermia reduces myocardial necrosis even when instituted after the onset of ischemia. Basic Res Cardiol 1997;92:351-357.
15. The Hypothermia after Myocardial Infarction Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-556.
16. Bernard S, Gray TW. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-563.
17. Rizik DG, Villegas BJ. Endovascular hypothermia in the setting of myocardial infarction complicated by cardiac arrest: A case report. Catheter Cardiovasc Interv 2003;59:201-204.
18. Dae MW, Gao DW, Sessler DI, Chair K, Stillson CA. Effect of endovascular cooling on myocardial temperature, infarct size, and cardiac output in human-sized pigs. Am J Physiol Heart Circ Physiol 2002;282:H1584-H1591.
19. Carrier M, Tourigny A, Thoribe N, et al. Effects of cold and warm blood cardioplegia assessed by myocardial pH and release of metabolic markers. Ann Thorac Surg 1994;58:764-767.
20. Ning XH, Xu CS, Song YC, et al. Hypothermia preserves function and signaling for mitochondrial biogenesis during subsequent ischemia. Am J Physiol 1998;274:H786-H793.
21. O'Neill WW, on behalf of the COOL-MI Investigators. Cooling as an adjunct to primary PCI for myocardial infarction. Presented at the Transcatheter Cardiovascular Therapeutics Conference, Washington, DC, September 2003.
22. Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 1994;267:H1948-H1954.
23. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000;342:626-633.
24. Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000;80: 1669-1699.
25. McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2004; 286:H1923-H1935.
26. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: The need for translation into clinical therapy. Circ Res 2004;95:125-134.
27. Ambrosio G, Tritto I. Reperfusion injury: Experimental evidence and clinical implications. Am Heart J 1999;138(2, Part 2):S69-S75.
28. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
29. Lefer AM. Role of selectins in myocardial ischemia-reperfusion injury. Ann Thorac Surg 1995;60:773-777.
30. Weis S, Shintani S, Weber A, et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004;113:885-894.
31. Berti F, Magni F, Rossoni G, De Angelis L, Galli G. Production and biologic interactions of prostacyclin and platelet-activating factor in acute myocardial ischemia in the perfused rabbit heart. J Cardiovasc Pharmacol 1990;16:727-732.
32. Maruyama M, Farber NE, Vercellotti GM, Jacob HS, Gross GJ. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs. Am Heart J 1990;120:510-520.
33. Montrucchio G, Alloatti G, Mariano F, et al. Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol 1990;137:71-83.
34. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995;146:419-428.
35. Coker SJ, Parratt JR, Ledingham IM, Zeitlin IJ. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 1981;291:323,324.
36. Lee CC, Appleyard RF, Byrne JG, Cohn LH. Leukotrienes D4 and E4 produced in myocardium impair coronary flow and ventricular function after two hours of global ischaemia in rat heart. Cardiovasc Res 1993;27:770-773.
37. Masini E, Bianchi S, Gambassi F, et al. Ischemia reperfusion injury and histamine release in isolated and perfused guinea-pig heart: Pharmacological interventions. Agents Actions 1990;30: 198-201.
38. Erlich JH, Boyle EM, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000;157:1849-1862.
39. Engler RL, Roth DM, del Balzo U, Ito BR. Intracoronary C5a induces myocardial ischemia by mechanisms independent of the neutrophil: Leukocyte filters desensitize the myocardium to C5a. FASEB J 1991;5:2983-2991.
40. Laffargue M, Calvez R, Finan P, et al. Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function. Immunity 2002; 16:441-451.
41. Hirsch E, Katanaev VL, Garlanda C, et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 2000;287:1049-1053.
42. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kγ-deficient mice. FASEB J 2001;15:2019-2021.
43. Alloatti G, Levi R, Malan D, et al. Phosphoinositide 3-kinase γ-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc Res 2003;60:242-249.
44. Hannigan M, Zhan L, Li Z, Ai Y, Wu D, Huang CK. Neutrophils lacking phosphoinositide 3-kinase γ show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis. Proc Natl Acad Sci USA 2002;99:3603-3608.
45. Jones GE, Prigmore E, Calvez R, et al. Requirement for PI 3-kinase γ in macrophage migration to MCP-1 and CSF-1. Exp Cell Res 2003;290:120-131.
46. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 2003;278:30725-30731.
47. Lian L, Wang Y, Draznin J, et al. The relative role of PLCb and PI3Kγ in platelet activation. Blood 2005;106:110-117.
48. Condliffe AM, Davidson K, Anderson KE, et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 2005;106:1432-1440.
49. Ali K, Bilancio A, Thomas M, et al. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 2004; 431:1007-1011.
50. Puri KD, Doggett TA, Douangpanya J, et al. Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue. Blood 2004;103:3448-3456.
51. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci 2005;30:194-204.
52. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000;101: 660-667.
53. Sen P, Mukherjee S, Ray D, Raha S. Involvement of the Akt/PKB signaling pathway with disease processes. Mol Cell Biochem 2003;253:241-246.
54. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004; 61:448-460.
55. Nagoshi T, Matsui T, Aoyama T, et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 2005;115:2128-2138.
56. Young LH, Ikeda Y, Scalia R, Lefer AM. Wortmannin, a potent antineutrophil agent, exerts cardioprotective effects in myocardial ischemia/reperfusion. J Pharmacol Exp Ther 2000;295:37-43.
57. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: A form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004;95:230-232.
58. Olander JV, Connolly DT, DeLarco JE. Specific binding of vascular permeability factor to endothelial cells. Biochem Biophys Res Commun 1991;175:68-76.
59. Bussolino F, Camussi G, Aglietta M, et al. Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol 1987; 139:2439-2446.
60. Milhoan KA, Lane TA, Bloor CM. Hypoxia induces endothelial cells to increase their adherence for neutrophils: Role of PAF. Am J Physiol 1992;263(3, Part 2):H956-H962.
61. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000;69:419-445.
62. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995;77:638-643.
63. Baines CP, Wang L, Cohen MV, Downey JM. Myocardial protection by insulin is dependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol 1999;94:188-198.
64. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004;109:2050-2053.
65. Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002;105:1497-1502.
66. Okumura H, Nagaya N, Itoh T, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 2004;109:242-248.
67. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase âinhibition during reperfusion in intact rat hearts. Circ Res 2004;94:960-966.
68. Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: The role of PI3K, Akt and eNOS. J Mol Cell Cardiol 2003;35:185-193.
69. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41:508-515.
70. Fujimoto H, Ohno M, Ayabe S, et al. Carbon monoxide protects against cardiac ischemia-reperfusion injury in vivo via MAPK and Akt-eNOS pathways. Arterioscler Thromb Vasc Biol 2004; 24:1848-1853.
71. Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 2000;87:309-315.
72. Tong H, Rockman HA, Koch WJ, Steenbergen C, Murphy E. G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ Res 2004;94: 1133-1141.
73. Kis A, Yellon DM, Baxter GF. Second window of protection following myocardial preconditioning: An essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol 2003;35:1063-1071.
74. Doukas J, Wrasidlo W, Noronha G, et al. A novel phosphoinositide 3-kinase inhibitor provides cardioprotection when delivered after myocardial reperfusion. Circulation 2005;112 (Suppl):253 (Abstract 1287).
75. Rizik D, Sharma S, Kent K, et al. A phase 1/2 trial of TG100-115, a phosphatidylinositol-3 kinase inhibitor, in acute ST elevation myocardial infarction patients treated by percutaneous coronary intervention indicates acceptable safety and pharmacokinetics at the initial dose level. J Am Coll Cardiol 2006;47 (Suppl):235A (Abstract 857-4).
76. Sterling DL, Thornton JD, Swafford A, et al. Hyperbaric oxygen limits infarct size in ischemic rabbit myocardium in vivo. Circulation 1993;88 (Part 1):1931-1936.
77. Thomas MP, Brown LA, Sponseller DR, et al. Myocardial infarct size reduction by the synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activator. Am Heart J 1990;120: 791-800.
78. Zamboni WA, Roth AC, Russell RC, et al. The effect of hyperbaric oxygen on reperfusion of ischemic axial skin flaps: A laser Doppler analysis. Ann Plast Surg 1992;28:339-341.
79. Zamboni WA, Roth AC, Russell RC, et al. Morphological analysis of the microcirculation during reperfusion of ischemic skeletal muscle and the effect of hyperbaric oxygen. Plast Reconstr Surg 1993;91:1110-1123.
80. Sunami K, Takeda Y, Hashimoto M, et al. Hyperbaric oxygen reduces infarct volume in rats by increasing oxygen supply to ischemic periphery. Crit Care Med 2000;28:2831-2836.
81. Sirsjo A, Lehr HA, Nolte D, et al. Hyperbaric oxygen treatment enhances the recovery of blood flow and functional capillary density in postischemic striated muscle. Circ Shock 1993;40:9-13.
82. Buras J. Basic mechanisms of hyperbaric oxygen in the treatment of ischemia-reperfusion injury. Int Anesthesiol Clin 2000;38:91-109.
83. Hills BA. A role for oxygen-induced osmosis in hyperbaric oxygen therapy. Med Hypotheses 1999;52:259-263.
84. Thom SR, Elbuken ME. Oxygen-dependent antagonism of lipid peroxidation. Free Radic Biol Med 1991;10:413-426.
85. Forman MB, Perry JM, Wilson BH, et al. Demonstration of myocardial reperfusion injury in humans: Results of a pilot study utilizing acute coronary angioplasty with perfluorochemical in anterior myocardial infarction. J Am Coll Cardiol 1991;18:911-918.
86. Wall TC, Califf RM, Blakenship J, et al. Intravenous fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. Circulation 1994;90:114-120.
87. Stavisky Y, Shandling AH, Ellestad MH, et al. Hyperbaric oxygen and thrombolysis in myocardial infarction: The 'HOT MI' Randomized Multicenter Study. Cardiology 1998;90:131-136.
88. 2-supersaturated infusate for regional correction of hypoxemia and production of hyperoxemia. Circulation 1997;96:4385-4391.
89. Spears JR, Henney C, Prcevski P, et al. Aqueous oxygen hyperbaric reperfusion in a porcine model of myocardial infarction. J Invasive Cardiol 2002;14:160-166.
90. Spears JR, Prcevski P, Xu R, et al. Aqueous oxygen attenuation of reperfusion microvascular ischemia in a canine model of myocardial infarction. ASAIO 2003;49:716-720.
91. Spears JR, Prcevski P, Jiang A, et al. Intracoronary aqueous oxygen perfusion, performed 24 h after the onset of postinfarction reperfusion, experimentally reduces infarct size and improves left ventricular function. Int J Cardiol (in press).
92. Trabattoni D, Bartorelli AL, Fabbiocchi F, et al. Hyperoxemic perfusion of the left anterior descending coronary artery after primary angioplasty in anterior ST-elevation myocardial infarction. Catheter Cardiovasc Interv 2006;67:859-865.
93. Warda HM, Bax JJ, Bosch JG, et al. Effect of intracoronary aqueous oxygen on left ventricular remodeling after anterior wall ST-elevation acute myocardial infarction. Am J Cardiol 2005; 96:22-24.